Gaha, T.M.c., Department of Microbiology, Mount Sinai School of Medicine, Box 1124, One Gustave L. Levy Place, New York, NY 10029, United States Kodera, T., Department of Microbiology, Mount Sinai School of Medicine, Box 1124, One Gustave L. Levy Place, New York, NY 10029, United States Phelps, R., Department of Pathology, Mount Sinai School of Medicine, Box 1124, One Gustave L. Levy Place, New York, NY 10029, United States Spiera, H., Department of Medicine, Mount Sinai School of Medicine, Box 1124, One Gustave L. Levy Place, New York, NY 10029, United States Pines, M., Institute of Animal Science, Volcani Center, Bet Degan, Israel Bona, C., Department of Microbiology, Mount Sinai School of Medicine, Box 1124, One Gustave L. Levy Place, New York, NY 10029, United States
The endpoint of pathogenic events in scleroderma is fibrosis of the skin and internal organs. Fibrosis in scleroderma results from the over synthesis and deposition of collagen in the connective tissue. The morbidity and mortality of the scleroderm is very high and presently there is no specific treatment. Halofuginone is a drug with great potential for the treatment of scleroderma since it inhibits the synthesis of collagen type I by fibroblasts. We have studied the in vivo effect of halofuginone in tight skin (TSK) mice that spontaneously develop a scleroderma-like disease due to a genetic defect. Our results demonstrate that halofuginone prevented the occurrence of skin scleroris when administered to newborn mice and reduced cutaneous hyperplasia when administered in adult TSK mice. These effects correlated with a decreased number of cells synthesizing collagen gene transcripts and a reduction in the level of autoantibodies specific for human target antigens. These results indicate that halofuginone may have use as a therapeutic in the treatment of fibrotic disease.
Effect of halofuginone on the development of tight skin (TSK) syndrome
35
Gaha, T.M.c., Department of Microbiology, Mount Sinai School of Medicine, Box 1124, One Gustave L. Levy Place, New York, NY 10029, United States Kodera, T., Department of Microbiology, Mount Sinai School of Medicine, Box 1124, One Gustave L. Levy Place, New York, NY 10029, United States Phelps, R., Department of Pathology, Mount Sinai School of Medicine, Box 1124, One Gustave L. Levy Place, New York, NY 10029, United States Spiera, H., Department of Medicine, Mount Sinai School of Medicine, Box 1124, One Gustave L. Levy Place, New York, NY 10029, United States Pines, M., Institute of Animal Science, Volcani Center, Bet Degan, Israel Bona, C., Department of Microbiology, Mount Sinai School of Medicine, Box 1124, One Gustave L. Levy Place, New York, NY 10029, United States
Effect of halofuginone on the development of tight skin (TSK) syndrome
The endpoint of pathogenic events in scleroderma is fibrosis of the skin and internal organs. Fibrosis in scleroderma results from the over synthesis and deposition of collagen in the connective tissue. The morbidity and mortality of the scleroderm is very high and presently there is no specific treatment. Halofuginone is a drug with great potential for the treatment of scleroderma since it inhibits the synthesis of collagen type I by fibroblasts. We have studied the in vivo effect of halofuginone in tight skin (TSK) mice that spontaneously develop a scleroderma-like disease due to a genetic defect. Our results demonstrate that halofuginone prevented the occurrence of skin scleroris when administered to newborn mice and reduced cutaneous hyperplasia when administered in adult TSK mice. These effects correlated with a decreased number of cells synthesizing collagen gene transcripts and a reduction in the level of autoantibodies specific for human target antigens. These results indicate that halofuginone may have use as a therapeutic in the treatment of fibrotic disease.